» Articles » PMID: 38770149

Impact of Medical-Pharmaceutical Separation Reform on Hospitalization Expenditure in Tertiary Public Hospitals: Difference-in-Difference Analysis Based on Panel Data from Beijing

Overview
Publisher Dove Medical Press
Specialty Public Health
Date 2024 May 21
PMID 38770149
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The medical-pharmaceutical separation (MPS) reform is a healthcare reform that focuses on reducing the proportion of drug expenditure. This study aims to analyze the impact of the MPS reform on hospitalization expenditure and its structure in tertiary public hospitals.

Methods: Using propensity score matching and multi-period difference-in-difference methods to analyze the impact of the MPS reform on hospitalization expenditure and its structure, a difference-in-difference-in-difference model was established to analyze the heterogeneity of whether the tertiary public hospital was a diagnosis-related-group (DRG) payment hospital. Of 22 municipal public hospitals offering tertiary care in Beijing, monthly panel data of 18 hospitals from July 2011 to March 2017, totaling 1242 items, were included in this study.

Results: After the MPS reform, the average drug expenditure, average Western drug expenditure, and average Chinese drug expenditures per hospitalization decreased by 24.5%, 24.6%, and 24.1%, respectively (P < 0.001). The proportions of drug expenditure decreased by 4.5% (P < 0.001), and the proportion of medical consumables expenditure increased significantly by 2.7% (P < 0.001).

Conclusion: The MPS reform may significantly optimize the hospitalization expenditure structure and control irrational increases in expenditure. DRG payment can control the tendency to increase the proportions of medical consumables expenditure after the reform and optimize the effect of the reform. There is a need to strengthen the management of medical consumables in the future, promote the MPS reform and DRG payment linkage, and improve supporting measures to ensure the long-term effect of the reform.

Citing Articles

Effects of a Diagnosis-Related Group Payment Reform on Length and Costs of Hospitalization in Sichuan, China: A Synthetic Control Study.

Liu Y, Du S, Cao J, Niu H, Jiang F, Gong L Risk Manag Healthc Policy. 2024; 17:1623-1637.

PMID: 38904006 PMC: 11189311. DOI: 10.2147/RMHP.S463276.

References
1.
Waszyk-Nowaczyk M, Guzenda W, Kamasa K, Pawlak K, Baltruszewicz N, Artyszuk K . Cooperation Between Pharmacists and Physicians - Whether It Was Before and is It Still Ongoing During the Pandemic?. J Multidiscip Healthc. 2021; 14:2101-2110. PMC: 8357703. DOI: 10.2147/JMDH.S318480. View

2.
Liu S, Lin H, Baine I, Wajnberg A, Gumprecht J, Rahman F . Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020; 26(11):1708-1713. DOI: 10.1038/s41591-020-1088-9. View

3.
Hinrichs-Krapels S, Diehl J, Hunfeld N, van Raaij E . Towards sustainability for medical devices and consumables: The radical and incremental challenges in the technology ecosystem. J Health Serv Res Policy. 2022; 27(4):253-254. DOI: 10.1177/13558196221110416. View

4.
Annear P, Kwon S, Lorenzoni L, Duckett S, Huntington D, Langenbrunner J . Pathways to DRG-based hospital payment systems in Japan, Korea, and Thailand. Health Policy. 2018; 122(7):707-713. DOI: 10.1016/j.healthpol.2018.04.013. View

5.
M V M, Sastry N, Moonesar I, Rao A . Predicting Universal Healthcare Through Health Financial Management for Sustainable Development in BRICS, GCC, and AUKUS Economic Blocks. Front Artif Intell. 2022; 5:887225. PMC: 9100561. DOI: 10.3389/frai.2022.887225. View